The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Osiris Therapeutics Inc

Nasdaq: OSIR
Last

(U.S.) $14.33

Today's change-0.15 -1.04%
Updated December 19 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Osiris Therapeutics Inc

Nasdaq: OSIR
Last

(U.S.) $14.33

Today's change-0.15 -1.04%
Updated December 19 4:00 PM -5GMT. Delayed by at least 15 minutes.

Reversal following new 50-day high

Osiris Therapeutics Inc closed lower Friday, dropping (U.S.)$0.15 or 1.04% to (U.S.)$14.33 after setting a new 50-day high. Over the last five days, shares have gained 10.91%, but are down 10.88% for the last year to date. Shares have underperformed the S&P 500 by 22.27% during the last year.

Key company metrics

  • Open(U.S.) $14.57
  • Previous close(U.S.) $14.48
  • High(U.S.) $14.98
  • Low(U.S.) $14.10
  • Bid / Ask-- / --
  • YTD % change-10.88%
  • Volume339,577
  • Average volume (10-day)118,029
  • Average volume (1-month)94,453
  • Average volume (3-month)103,426
  • 52-week range(U.S.) $11.80 to (U.S.) $18.41
  • Beta1.15
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.08
Updated December 19 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-5.23%

Osiris Therapeutics Inc has a net profit margin of -5.23%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue1713108
Total other revenue--------
Total revenue1713108
Gross profit131086
Total cost of revenue4322
Total operating expense16131111
Selling / general / administrative11986
Research & development1112
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income10-1-3
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax1-1-1-3
Income after tax1-1-1-1
Income tax, total000-1
Net income1-2-150
Total adjustments to net income--------
Net income before extra. items1-1-1-1
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1-1-1-1
Inc. avail. to common incl. extra. items1-2-150
Diluted net income1-2-150
Dilution adjustment----00
Diluted weighted average shares35343433
Diluted EPS excluding extraordinary itemsvalue per share0.02-0.04-0.02-0.04
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.02-0.04-0.02-0.04